|Table of Contents|

Experimental study on targeted therapy of gastric cancer with metastatic gastric cancer stem cell monoclonal antibody 6H6

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 20
Page:
3846-3850
Research Field:
Publishing date:

Info

Title:
Experimental study on targeted therapy of gastric cancer with metastatic gastric cancer stem cell monoclonal antibody 6H6
Author(s):
ZHANG Tao1; LI Jianzhou1; MA Xiaojun1; ZHENG Rui2; WANG Miaozhou3; SHU Xiong2
1.The Second People's Hospital of Xining,Qinghai Xining 810003,China;2.Beijing Jishuitan Hospital,the Affiliated Hospital of Capital Medical University/Beijing Institute of Trauma Department of Orthopedics,Beijing 100035,China；3.Qinghai University Affiliated Hospital,Qinghai Xining 810012,China.
Keywords:
metastatic gastric cancer stem cell; monoclonal antibody; 6H6; CD44
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2024.20.005
Abstract:
Objective:To identify a monoclonal antibody (McAb) 6H6 against metastatic gastric cancer stem cell,to provide candidate antibody drug for targeted therapy of gastric cancer.Methods:Flow cytometry was used to separate CD44(+) cells from SNU-16 to detect the expression of CD44 and antigen recognized by 6H6,which was detected by immunofluorescence.Serum-free suspension culture and Transwell assay were used to detect the self-renewal and invasion ability of CD44(+) cells from SNU-16 sorted by flow cytometry and CD44(+) cells treated by 6H6.The effect of 6H6 on cisplatin resistance was examined by CCK8.The inhibition of SNU-16 implanted tumor growth 6H6 combined with cisplatin was studied by tumor treatment experiments in nude mice.Results:Immunofluorescence showed that the antigen recognized by 6H6 could co-localize with CD44 on 6H6 cells.CD44(+) cells formed a significantly higher number of spheroid colonies compared with CD44(-) cells from SNU-16,which exhibited significantly increased invasion ability.6H6 suppressed the sphere formation of CD44(+) cells from SNU-16 (the inhibitory rate 35.8%)(P＜0.01).Meanwhile,6H6 can inhibit the invasive ability of CD44(+) cells from SNU-16 (the inhibitory rate 31.6%) (P＜0.01).6H6 also inhibited the drug-resistance of CD44(+) cells from SNU-16.The IC50 was 0.76 μg/mL in 6H6 group,and 1.98 μg/mL in control group.The experiment in vivo showed that 6H6 significantly inhibit the growth of transplanted tumor.When the concentration was high,its inhibitory effect reached 81.9%,and the antibody inhibitory effect was dose-dependent.Conclusion:The monoclonal antibody 6H6 can significantly inhibit the stem characteristics of metastatic gastric cancer stem cells in vitro,providing a valuable candidate targeted drug for gastric cancer.

References:

［1］ GUAN WL,HE Y,XU RH.Gastric cancer treatment:recent progress and future perspectives［J］.J Hematol Oncol,2023,16(1):57.
［2］ XIA JY,AADAM AA.Advances in screening and detection of gastric cancer［J］.J Surg Oncol,2022,125(7):1104-1109.
［3］ COSTA G,YOUNES H,KOURIE HR,et al.The rapidly evolving landscape of advanced gastric cancer therapy［J］.Future Oncol,2022,18(12):1413-1416.
［4］ ZHOU H,TAN L,LIU B,et al.Cancer stem cells:Recent insights and therapies［J］.Biochem Pharmacol,2023,209:115441.
［5］ RAO X,ZHANG C,LUO H,et al.Targeting gastric cancer stem cells to enhance treatment response［J］.Cells,2022,11(18):2828.
［6］ HAN J,WON M,KIM JH,et al.Cancer stem cell-targeted bio-imaging and chemotherapeutic perspective ［J］.Chem Soc Rev,2020,49(22):7856-7878.
［7］ NAIRUZ T,MAHMUD Z,MANIK RK,et al.Cancer stem cells:an insight into the development of metastatic tumors and therapy resistance［J］.Stem Cell Rev Rep,2023,19(6):1577-1595.
［8］ ZHOU L,WANG D,SHENG D,et al.NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer ［J］.Theranostics,2020,10(5):2405-2421.
［9］ SHU X,LIU H,PAN Y,et al.Distinct biological characterization of the CD44 and CD90 phenotypes of cancer stem cells in gastric cancer cell lines ［J］.Mol Cell Biochem,2019,459(1-2):35-47.
［10］ MAI Y,SU J,YANG C,et al.The strategies to cure cancer patients by eradicating cancer stem-like cells［J］.Mol Cancer,2023,22(1):171.
［11］ SHAIKH MV,CUSTERS S,ANAND A,et al.Cancer stem cells:Current challenges and future perspectives［J］.Methods Mol Biol,2024,2777:1-18.
［12］ OSUM M,KALKAN R.Cancer stem cells and their therapeutic usage［J］.Adv Exp Med Biol,2023,1436:69-85.
［13］ SINGH D,KHAN MA,SIDDIQUE HR.Specific targeting of cancer stem cells by immunotherapy:A possible stratagem to restrain cancer recurrence and metastasis［J］.Biochem Pharmacol,2022,198:114955.
［14］ PHILCHENKOV A,DUBROVSKA A.Cancer stem cells as a therapeutic target:Current clinical development and future prospective［J］.Stem Cells,2024,42(3):173-199.
［15］WANG Z,LI R,YANG G,et al.Cancer stem cell biomarkers and related signalling pathways［J］.J Drug Target,2024,32(1):33-44.
［16］ ZHANG Z,ZHANG Y.Transcriptional regulation of cancer stem cell:regulatory factors elucidation and cancer treatment strategies［J］.J Exp Clin Cancer Res,2024,43(1):99.

Memo

Memo:
青海省科技厅应用基础研究项目（编号：2020-ZJ-779）
Last Update: 1900-01-01